On 30 June 2025, Medtide Inc. (3880.HK, Medtide) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 514 million. CBI is honored to participate in the due diligence work for this IPO Project.

Medtide is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. 

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management and shareholders, providing information such as litigation, bankruptcy, winding-up and disqualification records. The due diligence project globally covered 4 countries and regions, including China, Hong Kong, the United States and the Republic of the Marshall Islands.